+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 1 Diabetes Drug Market by Form, End User - Global Forecast 2025-2030- Product Image
Type 1 Diabetes Drug Market by Form, End User - Global Forecast 2025-2030- Product Image
Sale

Type 1 Diabetes Drug Market by Form, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4985893
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 1 Diabetes Drug Market grew from USD 17.57 billion in 2023 to USD 19.14 billion in 2024. It is expected to continue growing at a CAGR of 9.06%, reaching USD 32.24 billion by 2030.

The Type 1 Diabetes Drug market encompasses pharmaceuticals that are essential for managing and treating Type 1 Diabetes, a condition characterized by the body's inability to produce insulin. Such drugs primarily include insulin formulations, adjunctive therapies like pramlintide, and emerging biologic drugs aiming to modulate immune response. Necessity arises from the chronic nature of the disease, requiring continuous blood sugar management to prevent complications. Applications primarily involve maintaining glycemic control in affected individuals, with end-use spanning hospitals, clinics, outpatient care facilities, and homecare settings. Market growth is propelled by increasing prevalence of Type 1 Diabetes, advancements in drug formulations like ultra-rapid-acting insulins, and the adoption of wearable digital technologies that streamline drug administration and monitoring. Potential opportunities are evident in personalized medicine approaches borne from genetic research, expanding access in emerging markets, and developments in closed-loop systems (artificial pancreas technology).

Challenges include the high cost of biologic drugs, regulatory hurdles in drug approvals, and potential side effects complicating widespread adoption. Additionally, intensified competition, cost-effective generic and biosimilar entries, and health infrastructure disparities in developing regions present notable hurdles to market expansion. Companies can innovate by focusing on improved drug delivery systems, integration of digital health solutions, and leveraging AI for precise dosing. Key areas like the development of oral insulins or drugs that enhance β-cell regeneration offer promising avenues for research. Understanding patient-centric care while navigating the competitive landscape with strategic pricing and collaborations remains critical. Pursuing advancements in biological understanding and applying them to drug development, alongside fostering partnerships for research and patient outreach, embodies the dynamic nature of this market. Continued innovation and responsiveness to regulatory expectations can bolster market performance, aligning efforts with emerging technological trends for sustainable growth.

Understanding Market Dynamics in the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing incidences of type 1 diabetes globally
    • Increasing healthcare expenditure with rising disposable income
    • Rising patient awareness on type 1 diabetes treatment
  • Market Restraints
    • Patent expiration of drugs
  • Market Opportunities
    • Emerging introduction of novel drugs to treat diabetes
    • Surge in research and development activities for type 1 anti-diabetic drugs
  • Market Challenges
    • Strict regulations for the approval drugs

Exploring Porter’s Five Forces for the Type 1 Diabetes Drug Market

Porter’s Five Forces framework further strengthens the insights of the Type 1 Diabetes Drug Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Type 1 Diabetes Drug Market

External macro-environmental factors deeply influence the performance of the Type 1 Diabetes Drug Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Type 1 Diabetes Drug Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, B. Braun Melsungen AG, Biocon Limited, DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XOMA Corporation.

Market Segmentation & Coverage

This research report categorizes the Type 1 Diabetes Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Form
    • Insulin Therapy
      • Long-Acting Insulin
      • Premix Analogs
      • Rapid Acting Insulin
    • Oral Medication
      • Biguanides
        • Metformine
        • Metformine Extended-Release
      • Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
        • Canaglifozine
        • Dapagliflozine
        • Empagliflozine
        • Ertugliflozine
  • End User
    • Drugstore
    • Hospital
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of type 1 diabetes globally
5.1.1.2. Increasing healthcare expenditure with rising disposable income
5.1.1.3. Rising patient awareness on type 1 diabetes treatment
5.1.2. Restraints
5.1.2.1. Patent expiration of drugs
5.1.3. Opportunities
5.1.3.1. Emerging introduction of novel drugs to treat diabetes
5.1.3.2. Surge in research and development activities for type 1 anti-diabetic drugs
5.1.4. Challenges
5.1.4.1. Strict regulations for the approval drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Type 1 Diabetes Drug Market, by Form
6.1. Introduction
6.2. Insulin Therapy
6.2.1. Long-Acting Insulin
6.2.2. Premix Analogs
6.2.3. Rapid Acting Insulin
6.3. Oral Medication
6.3.1. Biguanides
6.3.1.1. Metformine
6.3.1.2. Metformine Extended-Release
6.3.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
6.3.2.1. Canaglifozine
6.3.2.2. Dapagliflozine
6.3.2.3. Empagliflozine
6.3.2.4. Ertugliflozine
7. Type 1 Diabetes Drug Market, by End User
7.1. Introduction
7.2. Drugstore
7.3. Hospital
8. Americas Type 1 Diabetes Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Type 1 Diabetes Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Type 1 Diabetes Drug Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. TYPE 1 DIABETES DRUG MARKET RESEARCH PROCESS
FIGURE 2. TYPE 1 DIABETES DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2023 VS 2030 (%)
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. TYPE 1 DIABETES DRUG MARKET DYNAMICS
TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 48. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 49. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 50. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 51. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 54. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 57. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 80. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 81. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 82. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 83. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 86. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 87. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 88. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 89. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 98. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 99. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 100. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 101. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 134. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 135. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 136. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 137. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 154. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 155. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 156. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 159. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 160. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 161. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 162. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 165. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 166. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 167. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 168. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 171. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 172. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 173. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 174. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 177. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 178. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 179. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 180. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 189. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 190. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 192. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 207. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 208. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 209. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 210. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 213. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 214. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 215. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 216. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 219. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 220. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 221. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 222. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 243. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 244. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 245. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 246. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 261. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 262. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 263. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 264. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2023
TABLE 279. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Type 1 Diabetes Drug Market, which are profiled in this report, include:
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • B. Braun Melsungen AG
  • Biocon Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corporation

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 19.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 32.24 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Type 1 Diabetes: Epidemiology Forecast to 2033 - Product Image

Type 1 Diabetes: Epidemiology Forecast to 2033

  • Report
  • 69 Pages
  • Global
From
Oral Anti-Diabetic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029 - Product Image

Oral Anti-Diabetic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

  • Report
  • 150 Pages
  • Global
From
Japan Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Japan Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 70 Pages
  • Japan
From
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report 2024 - Product Image

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Type 2 Diabetes Pipeline Analysis Report - Product Image

Type 2 Diabetes Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From

About the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat Type 1 Diabetes, an autoimmune disorder in which the body's immune system attacks the cells that produce insulin. These drugs are used to help regulate blood sugar levels and reduce the risk of complications associated with the disease. Commonly used Type 1 Diabetes Drugs include insulin, sulfonylureas, meglitinides, and GLP-1 agonists. These drugs are typically administered orally or through injection. The Type 1 Diabetes Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.